JAZZ
Undervalued by 14.9% based on the discounted cash flow analysis.
Market cap | $7.13 Billion |
---|---|
Enterprise Value | $11.02 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $4.78 |
Beta | 0.64 |
Outstanding Shares | 63,039,618 |
Avg 30 Day Volume | 632,097 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 21.56 |
---|---|
PEG | -17.81 |
Price to Sales | 1.83 |
Price to Book Ratio | 1.89 |
Enterprise Value to Revenue | 2.87 |
Enterprise Value to EBIT | 20.29 |
Enterprise Value to Net Income | 33 |
Total Debt to Enterprise | 0.52 |
Debt to Equity | 1.54 |
No data
No data
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...